Frequency Therapeutics (FREQ) R&D Event
November 9, 2021
Frequency Therapeutics (FREQ) hosted a virtual R&D event on Tuesday, November 9th, 2021. The program included an update on advances for the Company’s FX-322 program for sensorineural hearing loss, as well as new potential restorative treatment programs for hearing loss and remyelination in multiple sclerosis.
Robert S. Langer, ScD
Frequency Therapeutics co-founder and MIT Institute Professor
Frequency Therapeutics co-founder and MIT Institute Professor
Carl LeBel, PhD
Chief Development Officer
Chief Development Officer
Kevin Franck, PhD
SVP, Strategic Marketing and New Product Planning
SVP, Strategic Marketing and New Product Planning
Sumit Dhar, PhD
Hugh Knowles Professor of Hearing Science and Associate Provost for Faculty at Northwestern University
Hugh Knowles Professor of Hearing Science and Associate Provost for Faculty at Northwestern University
Steven D. Targum, MD
Independent Consultant
Independent Consultant
Sanjay Magavi, PhD
VP, Myelination Research
VP, Myelination Research